CO2017004785A2 - N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a - Google Patents
N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2aInfo
- Publication number
- CO2017004785A2 CO2017004785A2 CONC2017/0004785A CO2017004785A CO2017004785A2 CO 2017004785 A2 CO2017004785 A2 CO 2017004785A2 CO 2017004785 A CO2017004785 A CO 2017004785A CO 2017004785 A2 CO2017004785 A2 CO 2017004785A2
- Authority
- CO
- Colombia
- Prior art keywords
- ylcarbonyl
- methylpyridine
- tetrahydropyran
- thiazol
- carboxamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente invención se refiere a dosis específicas de un antagonista de A2A para utilizarlo como un medicamento y, en particular, que sean útiles para el tratamiento de la enfermedad de Parkinson y del trastorno por déficit de atención con hiperactividad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400704 | 2014-12-03 | ||
PCT/EP2015/078181 WO2016087429A1 (en) | 2014-12-03 | 2015-12-01 | Low dosage a2a antagonist for the treatment of adhd and parkinsons |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017004785A2 true CO2017004785A2 (es) | 2017-08-31 |
Family
ID=58731664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0004785A CO2017004785A2 (es) | 2014-12-03 | 2017-05-12 | N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a |
Country Status (25)
Country | Link |
---|---|
US (2) | US20160158211A1 (es) |
EP (1) | EP3226863A1 (es) |
JP (1) | JP2017536400A (es) |
KR (1) | KR20170090430A (es) |
CN (1) | CN106999480A (es) |
AU (1) | AU2015357197A1 (es) |
BR (1) | BR112017011777A2 (es) |
CA (1) | CA2966582A1 (es) |
CL (1) | CL2017001407A1 (es) |
CO (1) | CO2017004785A2 (es) |
CR (1) | CR20170221A (es) |
DO (1) | DOP2017000121A (es) |
EA (1) | EA201790973A1 (es) |
EC (1) | ECSP17030050A (es) |
IL (1) | IL252355A0 (es) |
MA (1) | MA41090A (es) |
MX (1) | MX2017007027A (es) |
NI (1) | NI201700066A (es) |
PE (1) | PE20170926A1 (es) |
PH (1) | PH12017500923A1 (es) |
SG (1) | SG11201704370XA (es) |
SV (1) | SV2017005441A (es) |
TN (1) | TN2017000174A1 (es) |
TW (1) | TW201632186A (es) |
WO (1) | WO2016087429A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11884665B2 (en) | 2019-01-29 | 2024-01-30 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
US11999740B2 (en) | 2018-07-05 | 2024-06-04 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
CN114917350B (zh) * | 2022-06-21 | 2023-06-13 | 重庆医科大学附属第二医院 | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1700856E (pt) * | 2003-12-26 | 2016-02-19 | Kyowa Hakko Kirin Co Ltd | Derivado de tiazole |
WO2010010908A1 (ja) * | 2008-07-23 | 2010-01-28 | 協和発酵キリン株式会社 | 片頭痛治療剤 |
TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів |
-
2015
- 2015-11-30 MA MA041090A patent/MA41090A/fr unknown
- 2015-12-01 BR BR112017011777A patent/BR112017011777A2/pt not_active Application Discontinuation
- 2015-12-01 EA EA201790973A patent/EA201790973A1/ru unknown
- 2015-12-01 EP EP15802121.2A patent/EP3226863A1/en not_active Withdrawn
- 2015-12-01 KR KR1020177015211A patent/KR20170090430A/ko not_active Application Discontinuation
- 2015-12-01 CA CA2966582A patent/CA2966582A1/en not_active Withdrawn
- 2015-12-01 MX MX2017007027A patent/MX2017007027A/es unknown
- 2015-12-01 US US14/955,148 patent/US20160158211A1/en not_active Abandoned
- 2015-12-01 PE PE2017000864A patent/PE20170926A1/es not_active Application Discontinuation
- 2015-12-01 SG SG11201704370XA patent/SG11201704370XA/en unknown
- 2015-12-01 CR CR20170221A patent/CR20170221A/es unknown
- 2015-12-01 WO PCT/EP2015/078181 patent/WO2016087429A1/en active Application Filing
- 2015-12-01 CN CN201580064814.4A patent/CN106999480A/zh not_active Withdrawn
- 2015-12-01 TW TW104140137A patent/TW201632186A/zh unknown
- 2015-12-01 TN TN2017000174A patent/TN2017000174A1/en unknown
- 2015-12-01 JP JP2017529636A patent/JP2017536400A/ja not_active Withdrawn
- 2015-12-01 AU AU2015357197A patent/AU2015357197A1/en not_active Withdrawn
-
2017
- 2017-05-12 SV SV2017005441A patent/SV2017005441A/es unknown
- 2017-05-12 CO CONC2017/0004785A patent/CO2017004785A2/es unknown
- 2017-05-16 EC ECIEPI201730050A patent/ECSP17030050A/es unknown
- 2017-05-16 DO DO2017000121A patent/DOP2017000121A/es unknown
- 2017-05-17 IL IL252355A patent/IL252355A0/en unknown
- 2017-05-18 PH PH12017500923A patent/PH12017500923A1/en unknown
- 2017-06-01 NI NI201700066A patent/NI201700066A/es unknown
- 2017-06-02 CL CL2017001407A patent/CL2017001407A1/es unknown
- 2017-11-10 US US15/809,378 patent/US20180125835A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11999740B2 (en) | 2018-07-05 | 2024-06-04 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
US11884665B2 (en) | 2019-01-29 | 2024-01-30 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
Also Published As
Publication number | Publication date |
---|---|
SG11201704370XA (en) | 2017-06-29 |
CA2966582A1 (en) | 2016-06-09 |
IL252355A0 (en) | 2017-07-31 |
WO2016087429A1 (en) | 2016-06-09 |
PE20170926A1 (es) | 2017-07-13 |
CR20170221A (es) | 2017-10-05 |
PH12017500923A1 (en) | 2017-11-20 |
TN2017000174A1 (en) | 2018-10-19 |
JP2017536400A (ja) | 2017-12-07 |
BR112017011777A2 (pt) | 2018-02-20 |
EA201790973A1 (ru) | 2017-10-31 |
SV2017005441A (es) | 2017-08-25 |
US20160158211A1 (en) | 2016-06-09 |
MA41090A (fr) | 2017-10-10 |
AU2015357197A1 (en) | 2017-05-25 |
CN106999480A (zh) | 2017-08-01 |
TW201632186A (zh) | 2016-09-16 |
NI201700066A (es) | 2018-01-04 |
US20180125835A1 (en) | 2018-05-10 |
MX2017007027A (es) | 2017-08-24 |
DOP2017000121A (es) | 2017-07-15 |
ECSP17030050A (es) | 2017-08-31 |
CL2017001407A1 (es) | 2018-01-05 |
KR20170090430A (ko) | 2017-08-07 |
EP3226863A1 (en) | 2017-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
CL2017001438A1 (es) | Antagonistas de miostatina o activina para el tratamiento de sarcopenia | |
ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CO2017004785A2 (es) | N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a | |
CL2015002434A1 (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina. | |
CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
PE20171243A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados | |
BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
CR20160460A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
GT201600255A (es) | Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas | |
AR106415A1 (es) | Composición farmacéutica para el tratamiento del dolor | |
ITUB20169928A1 (it) | Formulazioni farmaceutiche per il trattamento del diabete | |
TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. | |
IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease |